feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

December meteor shower in India

trending

India Mexico tariff hike

trending

Malayalam actor Akhil Viswanth dead

trending

Officers join Indian Army parade

trending

Sunil Gavaskar personality rights case

trending

8th Pay Commission salary increase

trending

Noida Expressway speed limit reduced

trending

Nagaland Lottery results announced

trending

India U19 vs Pakistan U19

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Ozempic Arrives in India: Diabetes Drug Sparks Weight Loss Buzz

Ozempic Arrives in India: Diabetes Drug Sparks Weight Loss Buzz

13 Dec

•

Summary

  • Ozempic, a weekly diabetes injection, has launched in India.
  • It mimics gut hormones to regulate blood sugar and reduce appetite.
  • Medical experts stress strict supervision due to potential side effects.
Ozempic Arrives in India: Diabetes Drug Sparks Weight Loss Buzz

Ozempic, a once-weekly injectable medication developed for Type 2 diabetes management, has recently become available in India. This arrival marks a significant advancement, though medical experts are urging careful application under professional guidance. The drug has shown consistent efficacy in lowering blood sugar and maintaining glycemic control with a minimal risk of hypoglycemia since its global approval in 2017.

Globally, Ozempic's notable side effect of weight loss has fueled considerable interest, particularly among individuals managing obesity linked to diabetes or metabolic disorders. Primarily prescribed for adults with Type 2 diabetes who are overweight or have insufficient control with oral medications, it may also be considered for weight management with stringent medical oversight. It is crucial to understand that Ozempic is not intended for aesthetic purposes or casual weight loss.

Beyond its primary function, Ozempic offers kidney protection, with clinical trials indicating a nearly 24% reduction in the progression of kidney disease in diabetic patients. However, its use requires meticulous initiation and monitoring by trained specialists. Contraindications include a history of certain thyroid cancers or pancreatitis, and common side effects like nausea and digestive issues usually subside with proper titration and lifestyle adjustments.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Ozempic is a weekly injectable medication approved for managing Type 2 diabetes in India, helping to control blood sugar levels.
Yes, Ozempic has a notable side effect of weight loss, which has driven significant global interest beyond its diabetes treatment.
No, Ozempic requires strict medical supervision. It is not recommended for individuals with a history of certain thyroid cancers or pancreatitis, and self-medication is strongly discouraged.

Read more news on

Indiaside-arrowHealthside-arrow

You may also like

VinFast Eyes India's EV Two-Wheeler Market by 2026

1 Dec • 34 reads

article image

Safran Opens India's First Aircraft Engine MRO Hub

26 Nov • 94 reads

article image

Market Paradox: Inflows Halt Fall, IPOs Cap Rise

20 Nov • 87 reads

article image

SPARSH System Automates Pension Disbursement for Indian Military

12 Nov • 34 reads

article image

Groww's ₹6,632 Crore IPO Soars 13% on Debut, Defying Market Volatility

7 Nov • 32 reads

article image